NovoCure

$84.32 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About NovoCure

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Stock Analysis

last close $85.92
1-mo return 18.9%
3-mo return 41.5%
avg daily vol. 494.32T
52-week high 143.69
52-week low 56.39
market cap. $9.0B
forward pe -
annual div. -
roe -16.3%
ltg forecast -
dividend yield -
annual rev. $545M
inst own. 81.4%
baraka

Subscribe now for daily local and international financial news

Subscribe